

**CANADIAN SOCIETY OF TRANSPLANTATION
SOCIÉTÉ CANADIENNE DE TRANSPLANTATION
FINAL PROGRAM - February 22-25, 2012
PROGRAMME FINAL– du 22 au 25 février 2012**

TUESDAY, FEBRUARY 21 / LE MARDI 21 FÉVRIER 2012

0830-1630 CST Board Meeting (closed) – *Salon Rose*

1930-2130 CST Board & Council Dinner Meeting (closed) - *Salon Rose*

WEDNESDAY, FEBRUARY 22 / LE MERCREDI 22 FÉVRIER 2012

0700-1800 Registration – Inscription – *Verchères*

0800-1700 CST-AST 2012 JOINT SESSION – DIAGNOSTICS IN TRANSPLANTATION: FROM BENCH TO BEDSIDE-
Salle de Bal

0800-0805 Welcome – Drs. Robert Gaston and Tom Blydt-Hansen

0805-1000 Morning Session I: Antibody Testing – Paradigms Lost

Chairs: Drs. Elaine Reed and Kathryn Tinckam

0805-0820 HLA Testing: Current Technologies – Dr. Kathryn Tinckam

0820-0850 Antibody Diagnostics After Liver and Liver-Kidney Transplantation –
Dr. Jacqueline O’Leary

Objectives: Role of anti-HLA DSA in acute and chronic liver allograft and rejection. Impact of preformed anti-HLA DSA on OCI and SLKT outcomes. Importance of Class I vs Class II DSA in OLT and SLKT.

0850-0915 De Novo DSA After Lung Transplantation: Significance and
Therapeutic Options – Dr. Ramsey Hachem

0915-0940 Pathogenesis of Antibody-Mediated Injury in Heart Transplants:
Anti-HLA, Non-HLA, or Both? – Dr. Elaine Reed

Objectives: Increase participant knowledge about antibody mediated rejection. Discuss mechanisms of how antibodies contribute to the process of acute and chronic rejection. Discuss the clinical impact of antibodies to endothelial cells.

0940-1000 Refreshment Break - *Foyer*

1000-1200 Morning Session II: Diagnostics Challenges in Transplant Pathology

Chairs: Drs. Michael Mengel and Rene Rodriguez

1000-1030 Transplantation Pathology – SWOT Analysis of the Banff System -
Dr. Michael Mengel

Objectives: To give a historical overview of the Banff process. To present Strengths, weaknesses, opportunities and threats of the Banff process. To discuss the role of the Banff process in establishing diagnostics in transplantation.

1030-1100 Diagnosing Antibody-Mediated Rejection – The Significance of C4d –
Dr. Robert Colvin

Objectives: Recognize the criteria for diagnosing acute and chronic antibody-mediated rejection.

1100-1130 Infection Masquerading as Rejection – Dr. Parmjeet Randhawa

Objectives: To illustrate common infections after transplantation. To explain morphologic changes that help in differentiating infection and rejection. To discuss the role of the diagnostic laboratory in this clinical setting.

1130-1200 Are Protocol Biopsies Still Necessary For Managing Heart Transplant
Patients? – Dr. Rene Rodriguez

1200-1330 LUNCH - *Frontenac*

- 1330-1530 Afternoon Session I: Molecular Diagnostics in Transplantation**
Chairs: Drs. Phil Halloran and Shaf Keshavjee
- 1330-1400 Methods and Biostatistics in Molecular Diagnostics Methods and Biostatistics in Molecular Diagnostics** – Dr. Jeff Reeve
Objectives: To discuss some of the major biostatistical considerations related to microarray analysis in transplantation.
- 1400-1430 Molecular Assessment of Lung Transplants – New Targets for Intervention?** – Dr. Shaf Keshavjee
Objectives: Learn about ‘personalized medicine’ approach to donor organ assessment. Applications of molecular diagnostics in lung transplantation.
- 1430-1500 Integrating Molecular Diagnostics Into Patient Management and Clinical Trials** – Dr. Phil Halloran
Objectives: To review the molecular signals in biopsies for rejection and injury. To understand the mechanistic insights provided by molecular signals. To learn how molecular platforms can be used to change patient management by accurate assessment.
- 1500-1530 Refreshment Break** - Foyer
- 1530-1700 Afternoon Session II: Laboratory Support Strategies for the Incompatible Recipient**
Chairs: Drs. Patricia Campbell and H. Gebel
- 1530-1600 ABO Incompatible Transplantation** – Dr. Jennifer Conway
- 1600-1630 Appropriate Laboratory Support for Paired Exchange: Virtual Cross-Matching and Acceptable Mismatch versus Unacceptable Antigen**
Pro: Dr. Peter Nickerson; Con: Dr. Cathi Murphey
- 1630-1700 Panel Discussion** – Kathryn Tinckam, Peter Nickerson, Cathi Murphey

0700-1800

CST RESEARCH FELLOWS IN TRANSPLANTATION SYMPOSIUM (Research FITS) – Jacques Cartier et Place d’Armes

- 0700-1800 REGISTRATION – INSCRIPTION** – Verchères
- 0700-0745 Breakfast** - Place d’Armes
- 0745-0800 Welcome and Introduction** – Jacques-Cartier
Chairs: Drs. Patricia Birk and Tammy Keough-Ryan
- 0800-0845 Ethical and Legal Principles of Transplant Research** – Dr. Aviva Goldberg, Winnipeg, MB
Objectives: To discuss the ethical principles which guide medical research. To examine particularities of the transplant scenario that can create ethical quandaries for the transplant researcher. To explore methods of confronting these quandaries while continuing to promote high quality research.
- 0845-0930 State-of-the-Art Lecture**
Research Consortia: The Future of Clinical Research in Transplantation – Dr. Arthur Matas, Minnesota
Objectives: Understand advantages and limitations of single centre trials. Understand advantages and limitations of consortia. Understand specific cases where consortia may play a role.
- 0930-1000 Refreshment Break** - Place d’Armes
- 1000-1100 Principles of Clinical Study Design and Statistical Concepts** – Dr. Joseph Kim, Toronto, ON
Objectives: To review the major types of study designs in clinical research. To understand bias in clinical research and ways to minimize it. To outline some key statistical concepts that are useful to clinical researchers.
- 1100-1200 Trainees’ Presentations x 5**
- 1200-1300 Lunch and Networking** - Place d’Armes
- 1300-1400 Trainees’ Presentations x 5**

- 1400-1500 Career Choices in Transplantation: Clinical Research Track** –Dr. H. Grasemann, Toronto, ON
Objectives: Understand career opportunities in transplantation research. Design methods and analysis of clinical research studies.
- Career Choices in Transplantation: Basic Science & Translational Research Track** – Dr. Lisa Robinson, Toronto, ON
- 1500-1530 Refreshment Break** - Place d'Armes
- 1530-1700 Workshop: How to Give a High-Impact Presentation** – Dr. Hema Patel, Montréal, QC
Objectives: To discuss the characteristics of effective (and not effective) presentations. To review specific strategies that facilitates effectiveness in presentations. To encourage reflection on participants' own presentation strengths and challenges.
- 1700-1715 Closing Remarks** - Drs. Patricia Birk and Tammy Keough-Ryan
- 1715-1800 Awards Reception** - Bellevue

- 1800-2100 Canadian Paediatric Group Meeting** - Frontenac
- 1800-1830 Business Meeting (members only)**
- 1830-1930 Buffet Dinner (members only and invited speakers)**
- 1915-1930 CST Board Invitees**
- 1930-2100 Clinical Symposium: Adherence Post-Transplantation in Children: Why, When and How to Diagnosis It, Its Consequences on Outcomes and Potential Solutions** – Dr. Thomas Nevins, Minneapolis, MN and Dr. Beth Foster, Montréal, QC

THURSDAY, FEBRUARY 23 / LE JEUDI 23 FÉVRIER 2012

- 0700-1700 REGISTRATION – INSCRIPTION** - Verchères
- 0800-1500 CST GROUP MEETINGS** *(Breakfast on your own)*
- Canadian Liver Transplant Network** - Laval
 - Canadian Lung Transplant Group** - Bibliothèque
 - Canadian Kidney Transplant Group** - Jacques Cartier
 - Canadian HLA Group** - Place d'Armes
 - Canadian Pancreas Group** - Québec
 - Canadian Donation Group** - Salon Rose
 - CST Research Committee** – St-Louis 1-4
- 1000-1030 BREAK - PAUSE-** *(inside/outside meeting room)*
- 1200-1300 LUNCHEON** *(inside/outside meeting room)*
- 1400-1600 CST COUNCIL MEETING (Closed)** - Québec
- 1400-1530 Canadian Renal Transplant Study Group Meeting (Closed)** – Lévis
- 1600-1830 CST OPENING PLENARY SESSION 1** - Salle de Bal
Chairs: Drs. John Gill and Kathryn Tinckam
*(Simultaneous interpretation will be available for the Opening Session Only;
Le service d'interprétation simultanée sera disponible pour la séance d'ouverture seulement)*
- 1600-1615 Opening Remarks – CST President** – Dr. Tom Blydt-Hansen, Winnipeg, MB
- 1615-1700 Imaging the Immune System** – Dr. Michael Dustin, New York, NY
- 1700-1745 Organ Repair** – Dr. Shaf Keshavjee, Toronto, ON
*Objectives: Review concepts of organ preservation. Overview of organ repair strategies.
Overview concepts of ex-vivo organ repair.*

- 1745-1830 Operational Tolerance** – Dr. Jean-Paul Soulillou, Nantes, France
Objectives: Clinical and biological correlate of operational tolerance.
- 1830-1930 EXHIBITS OPEN- Reception amongst the exhibitors** - Frontenac
- 1830-1930 BK KIDNI TRIAL MEETING (Closed)** - St-Louis
- 1930-ON SOCIAL EVENING** - Salle de bal
Dinner with entertainment by The Marginal Donors' Band

FRIDAY, FEBRUARY 24 / LE VENDREDI 24 FÉVRIER 2012

- 0630-1200 REGISTRATION – INSCRIPTION** - Verchères
- 1600-1800 SUNRISE SYMPOSIUM** - Salle de bal
- 0630-0800 0630-0700 Breakfast** - Frontenac
- 0700-0800 Symposium – Non-Adherence to Immunosuppressant Medications**
Welcome – Introduction – Dr. John Gill, Vancouver, BC
- Session 1: Scope and Therapeutic Strategies** - Dr. Roz Mannon, South Birmingham, AL
Objectives: Attendees will understand the importance of non-adherence, how to identify at risk patient populations, and therapeutic strategies to prevent/treat this problem.
- Session 2: Patient Centered Strategies** – Ms. Rebecca Hayes
Objectives: Review patient engagement and motivational strategies before and after transplantation to improve adherence.
- Questions**
- 0700-ON SET-UP POSTERS (odd numbers)** - Petit Frontenac / Bellevue
- 0700-1300 EXHIBITS CONTINUE** - Frontenac
- 0800-1200 CST PLENARY SESSION 2 – CONCURRENT SESSIONS**

KIDNEY / PANCREAS – CST/CSN JOINT SPONSORED SESSION - Salle de bal

Chair: Dr. John Gill

- 0800-0900 Mechanisms of Glomerular Disease – Implications for Disease Recurrence After Transplantation** - Drs. Sue Quaggin, Toronto, ON, and Dr. David Salant, Boston, MA
Objectives (Dr. Salant): Describe the features of recurrent and de novo membranous nephropathy. Discuss the role of anti-PLA2R antibodies in recurrent membranous nephropathy. Discuss the features that distinguish recurrent and de novo membranous nephropathy.

Oral Abstracts

- 0900** Diagnosis Of Acute Rejection For Kidney Transplantation Using A Novel Blood-Based Biomarker Assay – Agnieszka Klimek-Abercrombie (*Vancouver, BC*) (Abstract # 1597)
- 0910** Living Donor Age and Kidney Transplant Outcomes: An Assessment of Risk Across the Age Continuum – Ruth Sapir-Pichdze (*Richmond Hill, ON*) (Abstract # 1614)
- 0920** Steroid-Free Immunosuppression Provides Equivalent Long Term Outcomes In Selected Renal Transplant Recipients – Jean Shapiro (*Vancouver, BC*) (Abstract # 1641)
- 0930** Donor Age Modifies the Effect of Delayed Graft Function on Long-term Outcomes – Sacha De Serres (*Québec, QC*) (Abstract # 1584)
- 0940** Increased Time-Dependent Variability In Tacrolimus Levels Is Associated With Inferior Outcomes Following Kidney Transplantation - Ruth Sapir-Pichdze (*Richmond Hill, ON*) (Abstract # 1615)

- 1000-1030 BREAK**

- 1030** The Influence Of Immediate Outcomes On Long-Term Results In Recipients Of Kidney Transplants From Standard Criteria Versus Expanded Criteria Donors – Nassima Smail (*Montréal, QC*) (Abstract # 1663)
- 1040** Regulation Of NK Cell-Mediated Tubular Epithelial Cell Death And Kidney Ischemia-Reperfusion Injury By NKR-P1 Receptors And Clr-B - James Yip (*London, ON*) (Abstract #1683)
- 1050** Enhanced Immune Function And Pro-Inflammatory Cytokines In Highly Sensitized Patients Awaiting Kidney Transplantation – Minh-Tri Nguyen (*Montréal, QC*) (Abstract #1698)
- 1100** BK Polyoma Virus Induces Epigenetic Reprogramming of Renal Epithelial Cells to Promote Cell Proliferation and Fibrosis – Vikas Srivastava (*Calgary, AB*) (Abstract #1702)

LUNG SESSION – St. Louis 1-4

Chair: Dr. Dale Lien

0800-0900 The Surgeon’s Laboratory - Dr. Joel Cooper, Philadelphia, PA

Objectives: To become familiar with the history of lung transplant patients. To appreciate the importance of pathophysiology in treatment of patients with COPD. To understand the importance of lab investigation in the development of new surgical procedures.

Oral Abstracts

- 0900** Phenotypic Characterization Of Natural Killer T Cells In Human Peripheral Blood, Spleen And Lungs – Malika Ladha (*Edmonton, AB*) (Abstract # 1700)
- 0915** An Assessment of the Effects of Iyengar Yoga on the Health-related Quality of Life of Patients with Chronic Respiratory Diseases: A Pilot Study – Maria Jose Santana (*Edmonton, AB*) (Abstract # 1660)
- 0930** Vaccination and Vaccine Responses in Pediatric Lung Transplant Recipients – Jackie Chiang (*Toronto, ON*) (Abstract # 1640)

0945-1015 BREAK

1015-1115 Making Sense of the Alphabet Soup: An Approach to the Sensitized Lung Transplant Patient – Dr. Kathryn Tinckam, Toronto, ON

1115-1215 The Highly Sensitized Lung Transplant Recipient: The Toronto Experience – Dr. Cecilia Chaparro, Toronto, ON

LIVER SESSION - Place d’Armes

Chairs: TBA

Recurrence of Disease in Liver Transplantation : Update on Prevention and Management

0800-0830 Recurrent Hepatitis B Post-OLT – Dr. Marie Laryea, Halifax, NS

Objectives: Understand the natural history of HCV recurrence following liver transplantation. Discuss options to reduce the risk and treatment/management of the HCV recurrence. Discuss indications, timing and outcomes of re-transplantation for recurrent HCV.

0830-0900 Auto-Immune Disease – Dr. Yaron Avitzur, Toronto, ON

Objectives: Overview of prevention and management of adult/pediatric auto-immune disease recurrences. Address and discuss specific post liver transplantation immunosuppressive management. Discuss indications, timing and outcomes of re-transplantation for recurrent auto-immune disease.

Oral Abstracts

- 0900** Pre-operative Stratification of Patients Undergoing Retransplantation of the Liver – Kris Croome (*London, ON*) (Abstract 1650)
- 0910** A retrospective analysis of cardiovascular risk factors in a liver transplant population – Holly Mansell (*Saskatoon, SK*) (Abstract # 1617)
- 0920** Do Preoperative Functional Mobility and MELD Score Affect Length of Stay Following Liver Transplantation? – Nancy Howes (*London, ON*) (Abstract # 1571)

- 0930** Evaluation of Blood Glucose Levels after Hepatitis B Immune Globulin Administration Utilizing Two Different Blood Glucose Monitoring Systems in the Acute Post Liver Transplant Setting – Thresiamma Lukose (*New York, NY*) (Abstract # 1661)
- 0940** Generation of a Recombinant Heme Oxygenase to Protect Transplanted Steatotic Livers from Reperfusion Injury – David Woodhall (*Halifax, NS*) (Abstract # 1699)
- 0950-1010** **BREAK**
- 1010** Pneumocystis Pneumonia In Solid Organ Transplant Recipients: Not Yet An Infection Of The Past - Erica Greanya (*Vancouver, BC*) (Abstract # 1652)
- 1020-1100** **Hepatocellular Carcinoma** – Dr. Norm Kneteman, Edmonton, AB
Objectives: Understand listing criteria for HCC, discuss management strategies on waitlist to reduce risk of recurrence and discuss indications, timing and outcomes of re-transplantation for recurrent HCC.

DONATION SESSION - Laval

Chair: Kevin Bradley

- 0800-0900** **Current and Novel Strategies to Increase Donor Lung Utilization** - Dr. Marcelo Cypel, Toronto, ON
- 0900** Cost Effectiveness Of A Strategy Of Paying To Increase Kidneys For Transplantation From Living Donors: A Decision Analysis – Lianne Barnieh (*Calgary, AB*) (Abstract # 1647)
- 0910** The Learning Curve Effect In A Canadian Donation After Cardiac Death (DCD) Kidney Transplant Program – Michael Moser (*Saskatoon, SK*) (Abstract # 1631)
- 0920** An Exercise in Age-Matching - Balancing Equity and Utility in Organ Allocation – Jagbir Gill (*Vancouver, BC*) (Abstract # 1666)
- 0930** Organ and Tissue Donation Required Referral Policy Development Implementation and Evaluation – Janet Evans (*Sydney, NS*) (Abstract # 1564)
- 0940** Exceptional Distribution: Analysis, Result After Transplantation – Ariane Morissette (*Montréal, QC*) (Abstract # 1645)
- 0950** System Design Improves Outcomes – Stephen Beed (*Halifax, NS*) (Abstract # 1639)
- 1000-1030** **BREAK**
- 1030** Chart Audit Process and Results – Corinne Corning (*Halifax, NS*) (Abstract #1600)
- 1040** Successful Outcome of Transplantation from a Multiorgan Donor With Herpes Encephalitis - Jean-François Lizé (*Montréal, QC*) (Abstract #1581)
- 1050** Practices Influencing Consent for Organ Donation – Clare Payne (*Toronto, ON*) (Abstract # 1593)
- 1100-1200** **Donation Organs: Creating a Legacy at the End of Life** - Dr. Michael DeVita, USA

HEART SESSION (Joint CST/CCTN Educational Meeting) - Jacques Cartier

Chairs: TBA

- 0800-0825** **Translating the Benefits of the Immature Immune System to Transplantation** - Dr. Simon Urschel, Edmonton, AB
- 0825-0850** **Research Update in CAV** – Dr. Michel White, Montréal, QC
- 0850-0930** **CMV Infection in Cardiac Transplantation: Update On Testing, Prevention and Treatment** - Dr. Atul Humar, Edmonton, AB
- 0930-0945** **BREAK**
- 0945-1115** **Oral Abstracts**
- Chairs: Drs. Bernard Cantin and MacKenzie Quantz
- 0945** CD133+ Stem Cells Used For Cardiac Regeneration May Be Destined For A Fibroblast Phenotype Resulting In Worsening Myocardial Fibrosis – Alec Falkenham (*Halifax, NS*) (Abstract # 1681)

- 0955** Morbidity And Mortality Of Infants Requiring Heart Transplantation In Western Canada: Waiting For An Answer – Desiree Machada (*Edmonton, AB*) (*Abstract #1667*)
- 1005** Investigating Differences In Adult And Infant B-Cell Receptor Signalling – Lauren Ryan (*Edmonton, AB*) (*Abstract # 1701*)
- 1015** Minimizing Donor Immunogenicity in Heart Transplantation Using siRNA – Xiufen Zheng (*London, ON*) (*Abstract # 1697*)
- 1025** Ex Vivo Assessment Of DCD Hearts With STEEN Solution Is Associated With Less Myocardial Edema And Improved Cardiac Function – Darren Freed (*Winnipeg, MB*) (*Abstract # 1685*)
- 1035** Pharmacogenetics of Tacrolimus in Pediatric Solid Organ Transplant Recipients – Seema Mital (*Toronto, ON*) (*Abstract # 1580*)
- 1045** A Comparison of Absorption Profiles Between Tacrolimus and Cyclosporine in Diabetic Cardiac Transplant Recipients – Chris White (*Winnipeg, MB*) (*Abstract #1635*)
- 1055** Impact Of Sildenafil Treatment On Pulmonary Hemodynamics And Outcomes In Patients With Severe Pulmonary Hypertension Receiving Heart Transplantation – Mario Sénéchal (*Montréal, QC*) (*Abstract # 1628*)
- 1105** Extra-Corporeal Membrane Oxygenation Temporary Support To Treat Early Graft Failure After Cardiac Transplantation – Éric Charbonneau (*Québec City, QC*) (*Abstract # 1642*)

- 1115-1200** **Antibody Testing and Approaches to Transplantation in Highly Sensitized Patients**
- Dr. Trish Campbell, Edmonton, AB
- 1200-1245** **LUNCH** – *Jacques Cartier* (for attendees at the CST/CCTN only)

1245-1630 **HEART – CCTN EDUCATION SESSION – Open To All CST Attendees - Jacques Cartier**
(*This educational program continues from the Heart Concurrent Organ Specific Session in the morning*)
Chairs: TBA

- 1245-1315** **Failing Fontans - When Should They Be Listed?** - Dr. Luke Burchill, Toronto, ON
- 1315-1345** **Short Term Mechanical Circulatory Support** – Dr. A. Cheung
- 1345-1445** **Miniaturization of Mechanical Support: Where are we Headed?** – Dr. William Cohn, Houston, TX
- 1445-1500** **BREAK**
- 1500-1540** **VAD Case Presentations**
- 1540-1620** **Transplantation Case Presentations**
- 1620-1630** **Evaluations**

1200-1600 ***** **LEISURE** *****

1200-1600 **CANADIAN PHARMACIST GROUP MEETING – Salon Rose**

- 1200-1220** **LUNCH** (*Pharmacist Group Members*)
- Educational Sessions (OPEN TO ALL DELEGATES)**
- 1220-1310** **Renal Transplantation and DVT Prophylaxis: To Bleed or to Clot?**
Cathy Burger, BScPhm, ACPR
- 1310-1400** **Is the Sky Falling? Resistant Organisms in Solid Organ Transplant Recipients**
Kathryn Slayter, BScPharmD, FCSHP
- 1400-1500** **Identifying and Managing Antibody in Transplantation**
Dr. Kathryn Tinckam
- 1500-1600** **Business Meeting (Pharmacist Group Members Only)**

1400-1600 **Paediatric Executive Group Meeting (Closed) - Lévis**

1600-1700	CST ETHICS FORUM – UNCONTROLLED DCD - <i>Salle de bal</i> Speaker: Dr. Douglas Hanto, New York, NY Chair: Dr. Annie Fecteau, Toronto, ON <i>Objectives: To understand key aspects of uncontrolled DCD. To understand ethical controversies around uncontrolled DCD. To understand how uncontrolled DCD may ethically proceed.</i>
1700-1830	CST PLENARY SESSION 3 – BASIC AND CLINICAL SCIENCE HIGHEST SCORING ABSTRACTS - <i>Salle de bal</i> Chairs: Drs. Prosanto Chaudhury and Simon Urschel <ul style="list-style-type: none"> 1700 Recipients of Kidneys From Expanded Criteria Donors Whose Egfr Does Not Drop >30% Between 1-12 Months After Transplantation Have Excellent Long-Term Graft Survival - Nassima Smail (<i>Montréal, QC</i>) (Abstract # 1670) 1710 Kidney Function at Time of Pancreas Transplantation Predicts Subsequent Risk Of End-Stage Renal Disease - Joseph Kim (<i>Toronto, ON</i>) (Abstract # 1612) 1720 5 Years Experience With Lung Donation After Cardiac Death - Marcelo Cypel (<i>Toronto, ON</i>) (Abstract # 1673) 1730 Does Expanded Criteria Donor Status Modify The Outcomes of Donation After Cardiac Death Kidney Transplantation? - Sunita Singh (<i>Toronto, ON</i>) (Abstract # 1611) 1740 Should The Worst Organ Go to The Least Sick Patient?:MELD and Donor Risk Index As Predictors Of Early Allograft Dysfunction – Roberto Hernandez-Alejandro (<i>London, ON</i>) (Abstract # 1649) 1750 Induction of Alloimmune Tolerance In Heart Transplantation Through Gene Silencing of TLR Adaptors - Xusheng Zhang (<i>London, ON</i>) (Abstract # 1688) 1800 Receptor Interacting Protein 3 (RIP3) Regulates Tubular Epithelial Cell (TEC) Injury and Inflammation Following Renal IRI - Arthur Lau (<i>London, ON</i>) (Abstract # 1679) 1810 Timing of Perfusate Infusion of CORM to Protect The Renal Transplant: Role Of Apoptosis - Kim Chi Tran, (<i>London, ON</i>) (Abstract # 1686) 1820 Establishment Of Nonmyeloablative Bone Marrow Chimerism By Double Negative Treg Cells Through Inducing T Cell Clonal Deletion and Suppressing NK Cell Function - Ye Su (<i>London, ON</i>) (Abstract # 1678)
1830-1945	CST ANNUAL GENERAL MEETING - <i>Salle de bal</i> CORR ANNUAL GENERAL MEETING - <i>Salle de bal</i> - Dr. Joe Kim CBS PRESENTATION - <i>Salle de bal</i> - Dr. Peter Nickerson
1945-2030	LIBATIONS AMONG THE POSTERS (Odd numbers) - <i>Petit Frontenac / Bellevue</i>
2030-ON	FREE EVENING

SATURDAY, FEBRUARY 25 / LE SAMEDI 25 FÉVRIER 2012

0630-1200	REGISTRATION – INSCRIPTION - <i>Verchères</i>
0630-0800	SUNRISE SYMPOSIUM - <i>Salle de bal</i> 0630-0700 Breakfast - <i>Frontenac</i> 0700-0800 Symposium - When Data is Not a Dirty Word: The Future of Canadian Information Management in Canadian Transplant Centres Welcome and Introduction : Drs. John Gill, Vancouver, BC and Marie-Josée Hébert, Montréal, QC Session 1: Innovative Uses of Registry Data, What is Possible? Dr. John Gill, Vancouver, BC <i>Objectives: Review advantages and limitations of registry data; provide real life examples where registry data have been used to advance quality of care, patient safety/support drug and therapeutic device innovation and acceptance into clinical practice.</i>

Session 2: CBS Strategies Plan – Dr. Peter Nickerson, Winnipeg, MB.
Objectives: Review CBC Plan for Information Management and highlight opportunities for innovation.

Session 3: Practical Considerations – Dr. Joe Kim, Toronto, ON
Objectives: Review key considerations and steps made to take advantage of the developments at CBS and align/integrate with CORR.

Questions

0700-ON SET-UP POSTERS (Even numbers) - *Petit Frontenac / Bellevue*

0700-1900 EXHIBITS CONTINUE - *Frontenac*

0800-1300 CST ALLIED HEALTH FORUM - *Jacques Cartier*

0800-0820 Welcome Address - Ms. Alyson Drabble

Invited Speaker - Dr. Tom Blydt-Hansen

0820-0915 Key Note Address - **The Future of HLA: How Reliable Are We In Predicting A Successful Transplant: The Pro's And Con's Of Virtual Cross Matching.**

Ms. Luz Stamm

0915-0930 Telehealth, The Future of Transplantation – Ms. Meny Davis

0930-1000 Diabetes Compliance: Can We Change the Future - Ms. Andrea Norgate

1000-1020 The Future Role of the Nurse Practitioner - Ms. Susan Chernenko

1020-1030 Camp For Children With Solid Organ Transplant Is More Than Just Fun. Exploring Experiences and Perceptions Surrounding Participation in Transplant Camp – Ms. Emily Ghent

1030-1040 BREAK

1040-1050 Nutrigenomics: The Future in Transplantation - Dr. Janet Madill

1050-1110 A Randomized Controlled Trial Evaluation of an Online e-Learning Medication Teaching Tool for Solid Organ Transplant Recipients - Ms. Jennifer Harrison
BScPhm, MSc

1110-1120 Business Meeting

1200-1300 Lunch and Networking

0800-1200 CST PLENARY SESSION 4 – BASIC AND CLINICAL SCIENCE PLENARY - *Salle de bal*

Chairs: Drs. Ian Alwayn and Greg Knoll

0800-0835 Innate and Adaptive Immunity – Dr. Jonathan Bromberg, Baltimore, MD

Objectives: Elucidate the signals that activate innate immunity. Define separate components of the innate immune system. Demonstrate the interactions between innate and adaptive immune mechanisms.

0835-0910 Innate and Adaptive Immunity – Dr. Joren Madsen, Boston, MA

Objectives: Compare and contrast the role of innate and adaptive alloresponses in organ transplantation. Show that innate immunity may play a greater role in organ transplantation than once thought. Review the current literature on the role of NK cells in allograft rejection and tolerance.

0910-0940 BREAK - Foyer

0940-1015 The Role of Complement in Organ Rejection – Dr. Bob Montgomery, Baltimore, MD
THE ANDREW LAZAROVITS LECTURE

1015-1050 The Role of Complement in Organ Rejection – Dr. Wink Baldwin, Cleveland, OH
Objectives: To review the complement components of relevance to organ rejection. To appreciate that complement has anti- as well as pro-inflammatory effects. To be aware of the consequences of modifying the complement response.

1050-1125 Viruses, Vaccines and Alloupregulation – Dr. Deepali Kumar, Edmonton, AB
Objectives: To learn about the consequences of influenza virus infections after transplant. To learn about the various preparations of influenza virus vaccines available for transplant patients. To learn about the controversy regarding vaccination and HLA alloupregulation and allograft rejection.

1125-1200 Viruses, Vaccine and Alloupregulation – Dr. Emilio Poggio, Cleveland, OH
Objectives: To review mechanisms of viral and alloimmune antigen recognition. To review animal models of cross-reactivity and heterologous immunity. To discuss recent human studies relating viral immunization with human and cellular immunity.

1200-1530

CST SPECIAL FORUM: FINANCIAL INCENTIVES TO INCREASE THE NUMBER OF ORGANS AVAILABLE FOR TRANSPLANTATION: EXPLORING CANADIAN CONSIDERATIONS AND POSSIBILITIES FOR RESEARCH - Salle de bal

OBJECTIVE: *Inform a strategy to study the use of incentives for organ donation in Canada.*

SUMMARY: *In this moderated and interactive session an expert panel will:*

- a) review current use of incentives for living and deceased organ donation in Canada and internationally
- b) review Canadian Public and Health Care Provider opinion regarding the use of incentives in living and deceased organ donation
- c) review legal and ethical considerations related to the use of incentives in organ donation in Canada
- d) review potential models of incentives in deceased and living organ donation
- e) critically review feasibility of a research study of incentives in deceased/living donation
- f) conduct roundtable discussion of next step

1200-1215 Boxed Lunch - Registration is required to receive lunch, but everyone is welcome to the Forum

1215-1220 Welcome – Dr. Tom Blydt-Hansen, CST President and Dr. Adeera Levin, Forum Chair

SESSION 1: CANADA’S ROLE

1220-1230 Declaration of Istanbul, Global Realities, Canadian Content - Dr. Ed Cole, Toronto, ON
Objectives: The problem of transplant tourism. What Istanbul declared? Canada’s response.

1230-1245 Definitions, Current Use of Incentives for Deceased and Living Donation in Canada/Internationally – Dr. Scott Klarenback, Edmonton, AB
Objectives: Provide an overview of the economics of living and deceased kidney donation. Describe the economic disincentives that may exist and evidence of their impact. Describe the potential role of economic incentives in deceased and living donation.

1245-1305 Canadian Survey Results – Dr. Lianne Barnieh, Calgary, AB

1305-1320 Discussion – Moderator – Dr. Adeera Levin, Vancouver, BC
Objectives: Increase awareness of DOI and implications for Canadian Neph/Tx. Promote understanding of need for information re incentives to inform decisions.

SESSION 2: LEGAL/ETHICAL CONSIDERATIONS AND POTENTIAL IMPACT ON EXISTING LIVING AND DECEASED DONATIONS

1320-1340 Legal Considerations – Mr. Tim Caulfield, Edmonton, AB

1340-1355 Incentives For Living and Deceased Organ Donation: Ethical Considerations -
- Dr. Aviva Goldberg, Winnipeg, MB

1355-1405 Impact on Organ Donation in Canada – Review Current Organ Donor Activity in Canada, and Discuss the Potential Impact of Incentives - Dr. John Gill

1405-1420 Discussion – Moderator – Dr. Adeera Levin, Vancouver, BC and Speakers including Dr. Linda Wright

SESSION 3: POTENTIAL MODELS, STUDY DESIGN CONSIDERATIONS

- 1420-1440 Principals and Potential Models** – Drs. Arthur Matas and Luis Tomatis
Objectives: Understand potential principles of incentives acceptable regulated systems. Understand potential living donor systems and what is required. Review potential models for incentives in LD and DD.
- 1440-1455 Study Design Considerations – Feasibility, Outcome Measures, Monitoring Impact, Translation of Results** – Dr. Greg Knoll, Ottawa, ON
- 1455-1515 Round Table Discussion of Questions – Defining Next Steps: Interactive Round-Table Discussion with all Participants and Audience Q and A.**
- Challenge Question: WHAT IS THE NEXT STEP? (Vote at end of meeting)**
- a) A Consensus Conference
 - b) Seek further opinion
 - c) A study of incentives in DD
 - d) A study of incentives in LD
 - e) Nothing – Incentives should not be studied in Canada for ethical reasons.
 - f) Something else - specify
- 1515-1530 Votes will be counted and announced.**

1200-1600 ***** LEISURE *****

1600-1700 CST DEBATE – What Level of Substance Use is Accepted in Donors, Recipients? - *Salle de bal*
 Moderator: Dr. Marcelo Cantarovich, Montréal, QC
 Speakers : Dr. Ian Alwayn, Halifax, NS and Dr. Susan Abbey, Toronto, ON

1700-1900 CST PLENARY SESSION 5 - *Salle de bal*
 Chairs : Drs. Michael Mengel and Dale Lien

1700-1800 Clinicopathologic Conference – Dr. Christine Cserti-Gazdewich, Toronto, ON
Objectives: Explain the potential significance of the donors red cell antibody screen.

1800-1900 What’s Hot in Transplant

1800-1820 Banff Meeting Update – Dr. Michael Mengel, Edmonton, AB
Objectives: To provide a summary of the 2011 Banff meeting. To discuss ongoing activities of the Banff Working Group.

1820-1840 ASHI Update – Dr. Paul Keown, Vancouver, BC
Objectives: Update on histocompatibility and immunogenetics of HLA. Update on sensitization and antibody detection. Update on immunological monitoring and new genomic/proteomic technologies.

1840-1900 ISHLT Update – Dr. Lori West, Edmonton, AB

1900-2000 LIBATIONS AMONG THE POSTERS (Even numbers) – *Petit Frontenac / Bellevue*

2000 - ON CST ANNUAL DINNER AND AWARDS - *Salle de bal*

MAINTENANCE OF CERTIFICATION - MAINTIEN DU CERTIFICAT

This event is an accredited group learning activity as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of General Surgeons.

La présente activité est approuvée par l'Association canadienne des chirurgiens généraux, constitue une activité de formation collective agréée conformément à la définition précisée dans le programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada.

CST BOARD - 2011 / 2012 - BUREAU DE DIRECTION DE LA SCT

President, Dr. Tom Blydt-Hansen
Past President, Dr. Marcelo Cantarovich
Vice-President, Dr. Steven Paraskevas
Treasurer, Dr. David Grant
Member at Large, Dr. Ian Alwayn
Member at Large, Dr. Atul Humar
Member at Large, Dr. Shafique Keshavjee
Member at Large, Dr. Patrick Luke
Member at Large, Dr. Eberhard Renner
Member at Large, Dr. Jean Tchervenkov
Member at Large, Associate Member, Ms. Alison Drabble

CST COUNCIL - 2012 - / CONSEIL DE LA SCT

Chair, Dr. Debra Isaac
Dr. Trish Campbell
Ms. Jennifer Harrison
Dr. Bryce Kiberd
Dr. Greg Grant

Dr. Dale Lien
Dr. Steven Paraskevas
Dr. Véronique Phan
Dr. Charles Scudamore
Ms. Jenny Wichart

CST SCIENTIFIC PROGRAM COMMITTEE- 2012 - COMITÉ DU PROGRAMME SCIENTIFIQUE DE LA SCT

Chair, John Gill
Co-Chair, Kathryn Tinckam
Ian Alwayn
Lorraine Bell
Jean-François Cailhier
Prosanto Chaudhury
A. Cheung
Christopher Daley
Edward Ferre

Dale Lien
Janet Madill
Michael Mengel
Thomas Mueller
Vicky Lee Ng
Michel Pâquet
Markus Selzner
Leroy Storsley
Simon Urschel